{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:35:12Z","timestamp":1786977312906,"version":"build-2736575974"},"reference-count":24,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"2","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Highly emetogenic chemotherapy induces emesis in cancer patients without prophylaxis. The purpose of this study was to evaluate the efficacy and safety of a fosaprepitant\u2010based triple antiemetic regimen for the prevention of chemotherapy\u2010induced nausea and vomiting (CINV) in patients with solid malignant tumors, determine risk factors and externally validate different personalized risk models for CINV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">This phase III trial was designed to test the non\u2010inferiority of fosaprepitant toward aprepitant in cancer patients who were to receive the first cycle of single\u2010day cisplatin chemotherapy. The primary endpoint was complete response (CR) during the overall phase (OP) with a non\u2010inferiority margin of 10.0%. Logistic regression models were used to assess the risk factors of CR and no nausea. To validate the personalized risk models, the accuracy of the risk scoring systems was determined by measuring the specificity, sensitivity and area under the receiver operating characteristic (ROC) curve (AUC), while the predictive accuracy of the nomogram was measured using concordance index (C\u2010index).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      A total of 720 patients were randomly assigned. CR during the OP in the fosaprepitant group was not inferior to that in the aprepitant group (78.1% vs. 77.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.765) with a between\u2010group difference of 0.4% (95% CI, \u20105.7% to 6.6%). Female sex, higher cisplatin dose (\u2265 70 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), no history of drinking and larger body surface area (BSA) were significantly associated with nausea. The AUC for the acute and delayed CINV risk indexes was 0.68 (95% CI: 0.66\u20100.71) and 0.66 (95% CI: 0.61\u20100.70), respectively, and the C\u2010index for nomogram CINV prediction was 0.59 (95% CI, 0.54\u20100.64). Using appropriate cutoff points, the three models could stratify patients with high\u2010 or low\u2010risk CINV. No nausea and CR rate were significantly higher in the low\u2010risk group than in the high\u2010risk group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Fosaprepitant\u2010based triple prophylaxis demonstrated non\u2010inferior control for preventing CINV in patients treated with cisplatin\u2010base chemotherapy. Female cancer patients without a history of alcohol consumption, with larger BSA and received high\u2010dose cisplatin might be more vulnerable to CINV. Three personalized prediction models were well\u2010validated and could be used to optimize antiemetic therapy for individual patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cac2.12397","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T03:32:58Z","timestamp":1671679978000},"page":"246-256","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Validation of different personalized risk models of chemotherapy\u2010induced nausea and vomiting: results of a randomized, double\u2010blind, phase III trial of fosaprepitant for cancer patients treated with high\u2010dose cisplatin"],"prefix":"10.34133","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7148-7608","authenticated-orcid":false,"given":"Yuanyuan","family":"Zhao","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South China","place":["Guangzhou, P. R. China"]},{"name":"Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China","place":["Guangzhou, P. R. China"]},{"name":"Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinlan","family":"Chen","sequence":"additional","affiliation":[{"name":"Jiangxi Cancer Hospital","place":["Nanchang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Liao","sequence":"additional","affiliation":[{"name":"Shaanxi Provincial Cancer Hospital","place":["Xi'an, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First People Hospital of Xiangtan","place":["Xiangtan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weineng","family":"Feng","sequence":"additional","affiliation":[{"name":"The First People Hospital of Foshan","place":["Foshan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Li","sequence":"additional","affiliation":[{"name":"Shenyang Tenth People's Hospital","place":["Shenyang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Weng","sequence":"additional","affiliation":[{"name":"Fuzhou Pulmonary Hospital of Fujian","place":["Fuzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Li","sequence":"additional","affiliation":[{"name":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefen","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Central Hospital of Lishui","place":["Lishui, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyong","family":"Ren","sequence":"additional","affiliation":[{"name":"Chongqing Three Gorges Central Hospital","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanda","family":"Lu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hainan Medical University","place":["Haikou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Chen","sequence":"additional","affiliation":[{"name":"Hunan Province Tumor Hospital","place":["Changsha, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenteng","family":"Liu","sequence":"additional","affiliation":[{"name":"Luoxin Pharmaceutical Group Co., Ltd","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhong","family":"Su","sequence":"additional","affiliation":[{"name":"Luoxin Pharmaceutical Group Co., Ltd","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Luoxin Pharmaceutical Group Co., Ltd","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China","place":["Guangzhou, P. R. China"]},{"name":"Collaborative Innovation Center for Cancer Medicine","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"27","key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl\u2010Daum B","year":"2006","unstructured":"Bloechl\u2010Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24((27)):4472\u20108.","journal-title":"J Clin Oncol"},{"issue":"24","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO Guideline Update","volume":"38","author":"Hesketh PJ","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark\u2010Snow RA, et\u00a0al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38((24)):2782\u201097.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_2_4_2","first-page":"277","article-title":"2016 Updated MASCC\/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy","volume":"25","author":"Herrstedt J","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, et\u00a0al. 2016 Updated MASCC\/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017;25((1)):277\u201088.","journal-title":"Support Care Cancer"},{"issue":"12","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy\u2010induced nausea and vomiting. Results from a randomized, double\u2010blind, placebo\u2010controlled trial in Latin America","volume":"97","author":"Poli\u2010Bigelli S","year":"2003","unstructured":"Poli\u2010Bigelli S, Rodrigues\u2010Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et\u00a0al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy\u2010induced nausea and vomiting. Results from a randomized, double\u2010blind, placebo\u2010controlled trial in Latin America. Cancer. 2003;97((12)):3090\u20108.","journal-title":"Cancer"},{"issue":"6","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of an aprepitant regimen with a multiple\u2010day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high\u2010dose cisplatin treatment","volume":"17","author":"Schmoll HJ","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli\u2010Bigelli S, Kim HK, Park K, Jordan K, et\u00a0al. Comparison of an aprepitant regimen with a multiple\u2010day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high\u2010dose cisplatin treatment. Ann Oncol. 2006;17((6)):1000\u20106.","journal-title":"Ann Oncol"},{"issue":"7","key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0091270007301800","article-title":"Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects","volume":"47","author":"Lasseter KC","year":"2007","unstructured":"Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, et\u00a0al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol. 2007;47((7)):834\u201040.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","article-title":"Single\u2010dose fosaprepitant for the prevention of chemotherapy\u2010induced nausea and vomiting associated with cisplatin therapy: randomized, double\u2010blind study protocol\u2013EASE","volume":"29","author":"Grunberg S","year":"2011","unstructured":"Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, et\u00a0al. Single\u2010dose fosaprepitant for the prevention of chemotherapy\u2010induced nausea and vomiting associated with cisplatin therapy: randomized, double\u2010blind study protocol\u2013EASE. J Clin Oncol. 2011;29((11)):1495\u2010501.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejphar.2013.10.015","article-title":"Prognostic factors for chemotherapy\u2010induced nausea and vomiting","volume":"722","author":"Warr D","year":"2014","unstructured":"Warr D. Prognostic factors for chemotherapy\u2010induced nausea and vomiting. Eur J Pharmacol. 2014;722:192\u20106.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"e_1_3_2_10_2","first-page":"14","article-title":"Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy\u2010induced nausea and vomiting","volume":"11","author":"Dranitsaris G","year":"2013","unstructured":"Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley\u2010Price P, et\u00a0al. Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy\u2010induced nausea and vomiting. J Support Oncol. 2013;11((1)):14\u201021.","journal-title":"J Support Oncol"},{"issue":"6","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.3747\/co.19.1074","article-title":"Prospective validation of risk prediction indexes for acute and delayed chemotherapy\u2010induced nausea and vomiting","volume":"19","author":"Bouganim N","year":"2012","unstructured":"Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, et\u00a0al. Prospective validation of risk prediction indexes for acute and delayed chemotherapy\u2010induced nausea and vomiting. Curr Oncol. 2012;19((6)):e414\u201021.","journal-title":"Curr Oncol"},{"issue":"2","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","article-title":"Risk Model\u2010Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early\u2010Stage Breast Cancer: A Randomized Clinical Trial","volume":"2","author":"Clemons M","year":"2016","unstructured":"Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, et\u00a0al. Risk Model\u2010Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early\u2010Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016;2((2)):225\u201031.","journal-title":"JAMA Oncol"},{"issue":"6","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy\u2010induced nausea and vomiting","volume":"28","author":"Dranitsaris G","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, et\u00a0al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy\u2010induced nausea and vomiting. Ann Oncol. 2017;28((6)):1260\u20107.","journal-title":"Ann Oncol"},{"issue":"2","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002476","article-title":"Personalized Estimate of Chemotherapy\u2010Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly\/Moderately Emetogenic Chemotherapy","volume":"95","author":"Hu Z","year":"2016","unstructured":"Hu Z, Liang W, Yang Y, Keefe D, Ma Y, Zhao Y, et\u00a0al. Personalized Estimate of Chemotherapy\u2010Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly\/Moderately Emetogenic Chemotherapy. Medicine (Baltimore). 2016;95((2)):e2476.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1034\/j.1399-6576.2000.440420.x","article-title":"Assessment of postoperative nausea using a visual analogue scale","volume":"44","author":"Boogaerts JG","year":"2000","unstructured":"Boogaerts JG, Vanacker E, Seidel L, Albert A, Bardiau FM. Assessment of postoperative nausea using a visual analogue scale. Acta Anaesthesiol Scand. 2000;44((4)):470\u20104.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"8","key":"e_1_3_2_16_2","first-page":"522","article-title":"Assessing the impact of chemotherapy\u2010induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index\u2010Emesis (FLIE) with 5\u2010day recall","volume":"11","author":"Martin AR","year":"2003","unstructured":"Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy\u2010induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index\u2010Emesis (FLIE) with 5\u2010day recall. Support Care Cancer. 2003;11((8)):522\u20107.","journal-title":"Support Care Cancer"},{"issue":"13","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial","volume":"328","author":"Kaye KS","year":"2022","unstructured":"Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, et\u00a0al. Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. Jama. 2022;328((13)):1304\u201014.","journal-title":"Jama"},{"issue":"5","key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.21037\/atm.2019.12.158","article-title":"Fosaprepitant versus aprepitant in the prevention of chemotherapy\u2010induced nausea and vomiting in patients receiving cisplatin\u2010based chemotherapy: a multicenter, randomized, double\u2010blind, double\u2010simulated, positive\u2010controlled phase III trial","volume":"8","author":"Zhang Z","year":"2020","unstructured":"Zhang Z, Yang Y, Lu P, Li X, Chang J, Zheng R, et\u00a0al. Fosaprepitant versus aprepitant in the prevention of chemotherapy\u2010induced nausea and vomiting in patients receiving cisplatin\u2010based chemotherapy: a multicenter, randomized, double\u2010blind, double\u2010simulated, positive\u2010controlled phase III trial. Ann Transl Med. 2020;8((5)):234.","journal-title":"Ann Transl Med"},{"issue":"9","key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","article-title":"Safety and efficacy of rolapitant for prevention of chemotherapy\u2010induced nausea and vomiting after administration of cisplatin\u2010based highly emetogenic chemotherapy in patients with cancer: two randomised, active\u2010controlled, double\u2010blind, phase 3 trials","volume":"16","author":"Rapoport BL","year":"2015","unstructured":"Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, et\u00a0al. Safety and efficacy of rolapitant for prevention of chemotherapy\u2010induced nausea and vomiting after administration of cisplatin\u2010based highly emetogenic chemotherapy in patients with cancer: two randomised, active\u2010controlled, double\u2010blind, phase 3 trials. Lancet Oncol. 2015;16((9)):1079\u201089.","journal-title":"Lancet Oncol"},{"issue":"2","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized phase III study evaluating the efficacy of single\u2010dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy\u2010induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","volume":"29","author":"Zhang L","year":"2018","unstructured":"Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, et\u00a0al. A randomized phase III study evaluating the efficacy of single\u2010dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy\u2010induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29((2)):452\u20108.","journal-title":"Ann Oncol"},{"key":"e_1_3_2_21_2","article-title":"Chemotherapy\u2010Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends","volume":"26","author":"Gupta K","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy\u2010Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. Cancer Treat Res Commun. 2021;26:100278.","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the Prevention of Chemotherapy\u2010Induced Nausea and Vomiting","volume":"375","author":"Navari RM","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et\u00a0al. Olanzapine for the Prevention of Chemotherapy\u2010Induced Nausea and Vomiting. N Engl J Med. 2016;375((2)):134\u201042.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/apt.16386","article-title":"Review article: the evolution of endpoint assessments for chemotherapy\u2010induced nausea and vomiting and post\u2010operative nausea and vomiting\u2010a perspective from the US Food and Drug Administration","volume":"54","author":"Gabby ME","year":"2021","unstructured":"Gabby ME, Bugin K, Lyons E. Review article: the evolution of endpoint assessments for chemotherapy\u2010induced nausea and vomiting and post\u2010operative nausea and vomiting\u2010a perspective from the US Food and Drug Administration. Aliment Pharmacol Ther. 2021;54((1)):7\u201013.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","article-title":"Chemotherapy\u2010Induced Nausea and Vomiting: Time for More Emphasis on Nausea?","volume":"20","author":"Ng TL","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M. Chemotherapy\u2010Induced Nausea and Vomiting: Time for More Emphasis on Nausea? Oncologist. 2015;20((6)):576\u201083.","journal-title":"Oncologist"},{"issue":"1","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","article-title":"Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin\u2010based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea","volume":"22","author":"Takemoto H","year":"2017","unstructured":"Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, et\u00a0al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin\u2010based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol. 2017;22((1)):88\u201095.","journal-title":"Int J Clin Oncol"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cac2.12397","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cac2.12397","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:49:21Z","timestamp":1773823761000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cac2.12397"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12397","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"2022-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}